Studies published since 2018 have detected microplastic particles in human stool samples, in placental tissue, in lung tissue from biopsy and autopsy specimens, in breast milk, in arterial plaque from cardiovascular surgery patients, and most recently in human bloodstream samples. The presence of these particles in human tissues is now an established fact across multiple independent laboratories using multiple analytical techniques. The disagreement, where it exists, is about concentration, particle composition, and biological significance.
The exposure pathways
The dominant routes of human microplastic exposure are inhalation (airborne fibers from synthetic textiles, dust, and outdoor particulate sources) and ingestion (food packaging, drinking water, marine seafood, table salt). The relative importance of these pathways is not yet well characterized for the general population and likely varies considerably with diet, geography, and indoor environmental conditions.
Estimates of typical exposure are noisy but converge in the range of tens to hundreds of thousands of particles per person per year. The smaller the particle size considered, the larger the count, but smaller particles are also progressively harder to measure with current methods, so estimates at the smallest size ranges should be treated as orders-of-magnitude rather than precise figures.
The biology, honestly stated
The biological consequences of these exposures, at currently observed concentrations, are not well established. Animal studies at concentrations several orders of magnitude above realistic human exposure have shown various effects on intestinal barrier function, immune system markers, and reproductive parameters. Whether these effects scale linearly down to human exposure levels, whether they integrate over time in ways relevant to chronic disease, and whether the chemical additives in plastics (rather than the polymer particles themselves) are the more relevant exposure variable are all open questions.
A 2024 study of patients undergoing carotid artery surgery found that those with detectable microplastic and nanoplastic particles in their atherosclerotic plaque had a substantially elevated rate of major cardiovascular events over the following three years. The study was widely covered. It is observational rather than causal, the sample size was modest, and replication has been mixed but is ongoing. The result raised the priority of cardiovascular endpoints in microplastic-toxicology research and is the closest thing to a clinically relevant signal that has emerged so far.
What is reasonable to conclude now
It is reasonable to conclude that human exposure to microplastics is universal in industrialized societies and large in absolute particle counts. It is reasonable to expect that the toxicology research currently underway will, over the next several years, establish more concretely whether and how this exposure matters at the population-health level. It is not reasonable, given the current state of evidence, to confidently dismiss the issue as harmless or to confidently assert that it accounts for any specific clinical condition.
The exposure side will keep growing as plastics production keeps growing. The biology will catch up to the question on its own timeline.